Brokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $171.44

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have earned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $171.44.

TMDX has been the subject of a number of research reports. Needham & Company LLC started coverage on TransMedics Group in a research note on Wednesday, August 21st. They set a “buy” rating and a $208.00 price target for the company. Canaccord Genuity Group raised their price objective on TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Cantor Fitzgerald started coverage on TransMedics Group in a research note on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective for the company. Stephens raised their price objective on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, TD Cowen raised their price objective on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, June 7th.

Insider Buying and Selling

In related news, insider Anil P. Ranganath sold 4,289 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total transaction of $652,785.80. Following the completion of the sale, the insider now directly owns 8,893 shares of the company’s stock, valued at approximately $1,353,514.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $8,948,714.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anil P. Ranganath sold 4,289 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total value of $652,785.80. Following the transaction, the insider now owns 8,893 shares in the company, valued at $1,353,514.60. The disclosure for this sale can be found here. In the last three months, insiders sold 61,247 shares of company stock valued at $9,650,880. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TMDX. Charles Schwab Investment Management Inc. increased its holdings in shares of TransMedics Group by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 253,517 shares of the company’s stock valued at $20,010,000 after acquiring an additional 4,343 shares during the period. Envestnet Portfolio Solutions Inc. increased its holdings in shares of TransMedics Group by 68.8% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 6,261 shares of the company’s stock valued at $494,000 after acquiring an additional 2,551 shares during the period. Principal Financial Group Inc. increased its holdings in shares of TransMedics Group by 21.3% in the 4th quarter. Principal Financial Group Inc. now owns 21,929 shares of the company’s stock valued at $1,731,000 after acquiring an additional 3,858 shares during the period. Level Four Advisory Services LLC purchased a new position in shares of TransMedics Group in the 4th quarter valued at $471,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of TransMedics Group in the 4th quarter valued at $889,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Price Performance

Shares of TransMedics Group stock opened at $156.08 on Friday. The stock has a 50 day moving average of $154.40 and a 200 day moving average of $127.98. TransMedics Group has a 12 month low of $36.42 and a 12 month high of $177.37. The firm has a market cap of $5.21 billion, a PE ratio of -459.06 and a beta of 1.99. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company had revenue of $114.30 million during the quarter, compared to analyst estimates of $98.84 million. During the same period in the prior year, the company earned ($0.03) earnings per share. The firm’s revenue was up 117.7% on a year-over-year basis. On average, research analysts expect that TransMedics Group will post 1.23 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.